Drug treatment in precocious puberty

Mark D. Wheeler, Dennis M Styne

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Precocious puberty, as defined by the onset of pubertal development before the age of 8 years in girls or 9 years in boys, can be classified into central and peripheral aetiologies. Central precocious puberty (CPP) results from early activation of the hypothalamic-pituitary-gonadal axis and has similar physical and hormonal characteristics to normal puberty. Extrapituitary gonadotrophin secretion or independent sex steroid secretion results in peripheral precocious puberty (PPP). Precocious puberty is characterised by rapid growth and advancement of skeletal age. The skeletal advancement is greater than the growth increase, so that final adult height is compromised. Long-acting gonadotrophin releasing hormone (GnRH) agonists are the current therapy of choice for central precocious puberty, having demonstrated effectiveness in halting the precocious development associated with this condition with minimal side effects. GnRH agonists are not effective as therapy for peripheral precocious puberty, but a number of other agents have been used with some success. These include androgen antagonists, testolactone, ketoconazole, and medroxyprogesterone acetate. The use of GnRH agonists has been associated with an increase in predictions of final height; however, continuing studies in treated cohorts are necessary to determine the true benefit of any of these agents on increasing ultimate height.

Original languageEnglish (US)
Pages (from-to)717-728
Number of pages12
JournalDrugs
Volume41
Issue number5
StatePublished - May 1991

Fingerprint

Drug therapy
Precocious Puberty
Gonadotropin-Releasing Hormone
Testolactone
Pharmaceutical Preparations
Androgen Antagonists
Medroxyprogesterone Acetate
Ketoconazole
Gonadotropins
Therapeutics
Puberty
Growth
Chemical activation
Steroids
Central Precocious Puberty

ASJC Scopus subject areas

  • Health, Toxicology and Mutagenesis
  • Toxicology

Cite this

Wheeler, M. D., & Styne, D. M. (1991). Drug treatment in precocious puberty. Drugs, 41(5), 717-728.

Drug treatment in precocious puberty. / Wheeler, Mark D.; Styne, Dennis M.

In: Drugs, Vol. 41, No. 5, 05.1991, p. 717-728.

Research output: Contribution to journalArticle

Wheeler, MD & Styne, DM 1991, 'Drug treatment in precocious puberty', Drugs, vol. 41, no. 5, pp. 717-728.
Wheeler MD, Styne DM. Drug treatment in precocious puberty. Drugs. 1991 May;41(5):717-728.
Wheeler, Mark D. ; Styne, Dennis M. / Drug treatment in precocious puberty. In: Drugs. 1991 ; Vol. 41, No. 5. pp. 717-728.
@article{39a9b972e3db4698b0cbec49eae69783,
title = "Drug treatment in precocious puberty",
abstract = "Precocious puberty, as defined by the onset of pubertal development before the age of 8 years in girls or 9 years in boys, can be classified into central and peripheral aetiologies. Central precocious puberty (CPP) results from early activation of the hypothalamic-pituitary-gonadal axis and has similar physical and hormonal characteristics to normal puberty. Extrapituitary gonadotrophin secretion or independent sex steroid secretion results in peripheral precocious puberty (PPP). Precocious puberty is characterised by rapid growth and advancement of skeletal age. The skeletal advancement is greater than the growth increase, so that final adult height is compromised. Long-acting gonadotrophin releasing hormone (GnRH) agonists are the current therapy of choice for central precocious puberty, having demonstrated effectiveness in halting the precocious development associated with this condition with minimal side effects. GnRH agonists are not effective as therapy for peripheral precocious puberty, but a number of other agents have been used with some success. These include androgen antagonists, testolactone, ketoconazole, and medroxyprogesterone acetate. The use of GnRH agonists has been associated with an increase in predictions of final height; however, continuing studies in treated cohorts are necessary to determine the true benefit of any of these agents on increasing ultimate height.",
author = "Wheeler, {Mark D.} and Styne, {Dennis M}",
year = "1991",
month = "5",
language = "English (US)",
volume = "41",
pages = "717--728",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Drug treatment in precocious puberty

AU - Wheeler, Mark D.

AU - Styne, Dennis M

PY - 1991/5

Y1 - 1991/5

N2 - Precocious puberty, as defined by the onset of pubertal development before the age of 8 years in girls or 9 years in boys, can be classified into central and peripheral aetiologies. Central precocious puberty (CPP) results from early activation of the hypothalamic-pituitary-gonadal axis and has similar physical and hormonal characteristics to normal puberty. Extrapituitary gonadotrophin secretion or independent sex steroid secretion results in peripheral precocious puberty (PPP). Precocious puberty is characterised by rapid growth and advancement of skeletal age. The skeletal advancement is greater than the growth increase, so that final adult height is compromised. Long-acting gonadotrophin releasing hormone (GnRH) agonists are the current therapy of choice for central precocious puberty, having demonstrated effectiveness in halting the precocious development associated with this condition with minimal side effects. GnRH agonists are not effective as therapy for peripheral precocious puberty, but a number of other agents have been used with some success. These include androgen antagonists, testolactone, ketoconazole, and medroxyprogesterone acetate. The use of GnRH agonists has been associated with an increase in predictions of final height; however, continuing studies in treated cohorts are necessary to determine the true benefit of any of these agents on increasing ultimate height.

AB - Precocious puberty, as defined by the onset of pubertal development before the age of 8 years in girls or 9 years in boys, can be classified into central and peripheral aetiologies. Central precocious puberty (CPP) results from early activation of the hypothalamic-pituitary-gonadal axis and has similar physical and hormonal characteristics to normal puberty. Extrapituitary gonadotrophin secretion or independent sex steroid secretion results in peripheral precocious puberty (PPP). Precocious puberty is characterised by rapid growth and advancement of skeletal age. The skeletal advancement is greater than the growth increase, so that final adult height is compromised. Long-acting gonadotrophin releasing hormone (GnRH) agonists are the current therapy of choice for central precocious puberty, having demonstrated effectiveness in halting the precocious development associated with this condition with minimal side effects. GnRH agonists are not effective as therapy for peripheral precocious puberty, but a number of other agents have been used with some success. These include androgen antagonists, testolactone, ketoconazole, and medroxyprogesterone acetate. The use of GnRH agonists has been associated with an increase in predictions of final height; however, continuing studies in treated cohorts are necessary to determine the true benefit of any of these agents on increasing ultimate height.

UR - http://www.scopus.com/inward/record.url?scp=0025893725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025893725&partnerID=8YFLogxK

M3 - Article

C2 - 1712706

AN - SCOPUS:0025893725

VL - 41

SP - 717

EP - 728

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 5

ER -